Detection of risk-identifying chromosomal abnormalities and genomic profiling by multiplex ligation-dependent probe amplification in chronic lymphocytic leukemia.
We performed genomic profiling using multiplex ligation-dependent probe amplification (MLPA) in 54 cases with suspected or advanced chronic lymphocytic leukemia (CLL). MLPA detected abnormalities when the percentage of mutated cells was greater than approximately 35%. Loss of 9p21 CDNK2A/B was revealed. MLPA is an economically attractive, powerful tool in trial-based, centralized risk-assessment for CLL.
Buijs
Arjan
A
Krijtenburg
Pieter Jaap
PJ
Meijer
Ellen
E
D002869:Chromosome Aberrations; D005260:Female; D005784:Gene Amplification; D018628:Gene Dosage; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D023281:Genomics / Q000379:methods; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000453:epidemiology / Q000235:genetics*; D008024:Ligands; D008297:Male; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D012307:Risk Factors
D008024:Ligands